Assyro AI

FDA Orange Book · active-ingredient family

Vinorelbine tartrate

Vinorelbine tartrate is approved as 1 brand and 11 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:NAVELBINE · NDA 020388

1

Brand (NDA)

11

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
NAVELBINERLDPIERRE FABRENDA 020388Dec 23, 1994

Generic (ANDA) products (11)

ProductApplicantApplicationTEApproved
VINORELBINE TARTRATEINGENUS PHARMS LLCANDA 208997Aug 05, 2019
VINORELBINE TARTRATEDR REDDYSANDA 202017APSep 12, 2013
VINORELBINE TARTRATEJIANGSU HANSOH PHARMANDA 091106APSep 26, 2012
VINORELBINE TARTRATERISINGANDA 200148Aug 31, 2012
VINORELBINE TARTRATEACTAVIS TOTOWAANDA 078011APJul 22, 2009
VINORELBINE TARTRATEEBEWE PHARMAANDA 078408Feb 13, 2008
VINORELBINE TARTRATEHOSPIRAANDA 076827Jun 02, 2005
VINORELBINE TARTRATEFRESENIUS KABI USAANDA 076849Apr 18, 2005
VINORELBINE TARTRATEHIKMAANDA 076461APDec 11, 2003
VINORELBINE TARTRATEHIKMAANDA 075992APJun 10, 2003
VINORELBINE TARTRATETEVA PHARMS USAANDA 076028Feb 03, 2003

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Vinorelbine tartrate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.